Navigation Links
Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion
Date:11/8/2010

bbott) and Casodex (bicalutamide; AstraZeneca). Despite losing around 54% of its current sales value to generic competitors, Arimidex will retain its market leading position.

In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2009, with an antihormonals portfolio valued at over $3.2 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.

Reasons to Purchase*Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2009 to 2019

*Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth

*Benchmark antihormonal therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot

OVERVIEW 1

Catalyst 1

Summary 1

About Datamonitor healthcare 2

About the Oncology pharmaceutical analysis team 2

EXECUTIVE SUMMARY 3

Strategic scoping and focus 3

Datamonitor insight into the antihormonal cancer therapies market 3

Related reports 4

Upcoming related reports 4

Table of Contents 5

MARKET DEFINITION 6

Definition of the cancer market 6

Antihormonal therapies by ATC class 6

L2A3 - Luteinizing hormone-releasing hormone agonists 6

L2B1 - Anti-estrogens 7

L2B2 - Anti-androgens 7

L2B3 - Aromatase inhibitors 7

L2B9 - Other hormone antagonists 7

MARKET OVERVIEW 9

Seven major markets 10

Current and future market overview 10

The antihormonals market will shrink marginally in the forecast period 10

Patent expiries of leading antihormonal brands are set to occur within the next 5 years 10

The US will suffer the greatest
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
2. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
3. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
4. High Unemployment Rates in North Carolina Will Continue to Dictate the Decrease of Commercial Health Plan Enrollment and the Increase of Medicaid Enrollment
5. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
6. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
7. Biocon and Pfizer Enter Into Global Commercialization Agreement
8. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
9. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
10. IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery
11. Concentric Medical Announces Commercial Launch of Trevo™ in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  ResMed ... availability of the ResMed Data Exchange program, a ... home medical equipment (HME) and other health care ... timely, secure access to critical patient information. It ... ResMed,s AirView™ and U-Sleep™ patient management platforms with ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
(Date:10/20/2014)... Pharmaceutic Labs announces the opening of its ... NY for admixing, compounding, drug shortages and ... the FDA standards for safety and quality, using 21 ... The 10,000 square foot outsourcing facility was ... and quality control. The company will produce sterile and ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Reduced By an Average of More Than ... N.C., April 02, 2007 /PRNewswire/ --,Adding the ... 24-Hour(TM) Extended-Release Tablets to,Parkinson's patients' existing levodopa ... to continue,their daily activities for a longer ...
... MUNICH, Germany, April 03, 2007 /PRNewswire/ -- ... showing the,improved potency of oritavancin to stop ... common wetting agent (polysorbate 80) and one,study ... in a mouse model of pneumonia. Oritavancin, ...
Cached Medicine Technology:Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Viejo, California (PRWEB) October 20, 2014 Final ... announced the release of the Citrus theme for FCPX ... I would use to describe the Citrus theme” Says Christina ... so easy to look so professional.” , Citrus comes with ... Included with the template are: four transitions for added style, ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium ... lot to celebrate this month. October marks Italian Heritage Month ... contributions of Americans of Italian heritage and Italians in America. ... shares its favorite Italian cocktails and encourages everyone to enjoy ... if it is only in a glass. , Punzoné ...
(Date:10/19/2014)... October 20, 2014 Hastings and Hastings, ... years of service throughout the greater Phoenix area and ... representation with regard to catastrophic automobile accidents. Statistics have ... country and throughout Arizona. As such, Hastings and Hastings ... legal representation for those who have been injured through ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... treatment vs. watchful waiting , MONDAY, July 27 (HealthDay ... who have prostate cancer surgery but leaves unanswered the complicated ... treatment or just watchful waiting. , The study of almost ... removal of a cancerous prostate gland -- between 1987 and ...
... , , WASHINGTON, ... the National Press Club. National Press Club events are open to ... and Newsmakers. Events listed are subject to last-minute changes. Space may ... time and avoid waiting in line, tickets can be paid for ...
... (LRF) is pleased to announce that the 2009 Millennium ... has been awarded to Kai Fu, MD, PhD, Associate ... , Lymphoma, the most common type of ... and non-Hodgkin lymphoma (NHL). According to a 2008 ...
... in never-smokers is poorly understood, but a study led by ... at the National Cancer Institute has identified a molecule believed ... , The findings, published online recently in the Proceedings ... improved therapy for lung cancer in both never-smokers and smokers, ...
... , , PITTSBURGH, July 27 Childhood ... young adults and can lead to premature death in adulthood ... hypertension. In addition to its significant human toll, childhood obesity ... annually. , , To address the continued ...
... A ... the American Society of Andrology,s annual meeting. Study results showed marked improvement in sperm ... the ejaculate. , ... Bellingham, WA (PRWEB) July 23, 2009 -- A clinical study for the male fertility ...
Cached Medicine News:Health News:Men Who Have Prostate Cancer Surgery Do Well 2Health News:Men Who Have Prostate Cancer Surgery Do Well 3Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2Health News:Molecule plays early role in nonsmoking lung cancer 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 2Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 3Health News:Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: